These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32024071)

  • 1. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab.
    Scarozza P; Marafini I; Laudisi F; Troncone E; Schmitt H; Lenti MV; Costa S; Rocchetti I; De Cristofaro E; Salvatori S; Frezzati L; Di Sabatino A; Atreya R; Neurath MF; Calabrese E; Monteleone G
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32024071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
    Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
    Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
    Quénéhervé L; Trang-Poisson C; Fantou A; Flamant M; Durand T; Bouguen G; Bregeon J; Oullier T; Amil M; Dewitte M; Bardot S; Blandin S; Braudeau C; Vibet MA; Josien R; Neunlist M; Bourreille A
    PLoS One; 2024; 19(4):e0298313. PubMed ID: 38564601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn's Disease.
    Kapila N; Flocco G; Shen B; Modaresi Esfeh J
    Cureus; 2018 Jul; 10(7):e3080. PubMed ID: 30305988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.
    Takatsu N; Hisabe T; Higashi D; Ueki T; Matsui T
    Core Evid; 2020; 15():7-20. PubMed ID: 32280316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina.
    Salkić N; Bašić Denjagić M; Zubčević N; Tamburić R; Husić Selimović A; Babić E; Bevanda M; Saray A; Jovanović P; Tošić Z; Dobrovoljski A; Barać T
    Biomol Biomed; 2024 Apr; ():. PubMed ID: 38683174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis.
    Miyazaki H; Hoshi N; Ishida T; Nishioka C; Ouchi S; Shirasaka D; Yoshie T; Munetomo Y; Sakamoto Y; Osuga T; Matsui S; Hyodo T; Denda T; Watanabe D; Ooi M; Kodama Y
    Sci Rep; 2023 Nov; 13(1):20262. PubMed ID: 37985889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging treatments for ulcerative colitis: a focus on vedolizumab.
    Gledhill T; Bodger K
    Biologics; 2013; 7():123-30. PubMed ID: 23723689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis.
    Alghamdi M; Alyousfi D; Mukhtar MS; Mosli M
    Saudi J Gastroenterol; 2024 Jun; ():. PubMed ID: 38847060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence of Drug-Induced Lupus Secondary to Vedolizumab Use in a Patient With Crohn's Disease.
    Rodriguez VI; Mathavan A; Mathavan A; Rodriguez DN; Alvarez CS; Pham A
    ACG Case Rep J; 2024 Jan; 11(1):e01270. PubMed ID: 38274296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab, an α4β7-Integrin Inhibitor, Exacerbates Ulcerative Colitis-Related Spondylitis.
    Yamamoto H; Taniguchi Y
    J Clin Rheumatol; 2024 Jul; ():. PubMed ID: 38982566
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients.
    Breidert M; Eftekhari P; Louis F; Rotoiu C; Rath T; Neurath MF; Atreya R
    Crohns Colitis 360; 2020 Apr; 2(2):otaa037. PubMed ID: 32776006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford.
    Pulusu SSR; Srinivasan A; Krishnaprasad K; Cheng D; Begun J; Keung C; Van Langenberg D; Thin L; Mogilevski T; De Cruz P; Radford-Smith G; Flanagan E; Bell S; Kashkooli S; Sparrow M; Ghaly S; Bampton P; Sawyer E; Connor S; Rizvi QU; Andrews JM; Mahy G; Chivers P; Travis S; Lawrance IC
    World J Gastroenterol; 2020 Aug; 26(30):4428-4441. PubMed ID: 32874055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis.
    Perry C; Fischer K; Elmoursi A; Kern C; Currier A; Kudaravalli P; Akanbi O; Tripathi N; Yarra P; Su L; Flomenhoft D; Stromberg A; Barrett TA
    Dig Dis Sci; 2021 Jun; 66(6):2051-2058. PubMed ID: 32710192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
    Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
    United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario.
    Zingone F; Barberio B; Compostella F; Girardin G; D'Incà R; Marinelli C; Marsilio I; Lorenzon G; Savarino EV
    Therap Adv Gastroenterol; 2020; 13():1756284820936536. PubMed ID: 32695231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness.
    Zezos P; Kabakchiev B; Weizman AV; Nguyen GC; Narula N; Croitoru K; Steinhart AH; Silverberg MS
    J Can Assoc Gastroenterol; 2020 Apr; 3(2):74-82. PubMed ID: 32328546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
    Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
    J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.